Loading stock data…
ABBV
$207.00-1.22 (-0.59%)
Market OpenUpdated 9:39 AM EDT
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AbbVie Inc. in the Healthcare sector is trading at $208.16. The stock is currently 15% below its 52-week high of $244.81, remaining 3.1% below its 200-day moving average. Technical signals show neutral RSI of 49 and bullish MACD crossover, explaining why ABBV maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$207.00
Potential Downside
106%
Whystock Fair Value$-12.32
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus30 analysts
Buy
Mean target$250.33+20.9%
Range$184.00 – $294.00
Fundamentals
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$354.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
84.24
Beta
Defensive asset. Lower volatility than the S&P 500.
0.36
Div Yield
Strong income play. Yield provides a meaningful total return floor.
337.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-115.08%
Volume
Today's trading volume
150,352
Recent News
AbbVie's Latest Results Reveal a Trend Investors Shouldn't Overlook
But is the stock a buy on the dip?
3 of the Best Dividend Stocks to Buy in May 2026
These stocks offer high yields, attractive valuations, significant upside, and can be terrific investments to buy right now.
ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
ABBV jumps 5% after a Q1 beat and higher 2026 guidance, but Skyrizi, Rinvoq and a deep pipeline may matter more for its post-earnings outlook
MercadoLibre And 2 Other Stocks That May Be Priced Below Their Estimated Value
The market remained flat over the last week, yet it has risen by 28% over the past year with earnings expected to grow by 16% per annum in the coming years. In such an environment, identifying stocks that are potentially undervalued can offer opportunities for investors seeking to capitalize on discrepancies between current prices and estimated intrinsic values.
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?
ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.